Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

On CNBC's “ Halftime Report Final Trades ,” Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of ...

Amgen may be the more expensive stock, but several things suggest that it deserves its valuation premium and that its stock price can keep climbing. Amgen is generating stronger growth.